LSE:HVO (hVIVO Plc)
About HVO
hVIVO plc is a United Kingdom-based specialist contract research organization (CRO). The Company is engaged in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. It provides end-to-end early clinical development services to its client base, which includes global biopharma companies. It offers a portfolio of approximately 10+ human challenge models to test a range of infectious and respiratory disease products, challenge agent manufacturing, specialist drug development, and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. It offers additional clinical field trial services, such as patient recruitment and clinical trial site services. It runs challenge studies in from its Whitechapel quarantine clinic, and its QMB clinic with its specialized on-site virology and immunology laboratory.
hVIVO Plc (LSE: HVO) Latest News
Investing Articles
2 under-the-radar growth stocks I’ve just bought for my Stocks and Shares ISA
Investing Articles
Is hVIVO still a top UK stock for growth after today’s full-year results?
Investing Articles
1 ex-penny stock I’d buy in March while it is 27p
Investing Articles
Here’s how I’d start investing in UK stocks with just £500
Investing Articles
How I built £4,000 of passive income starting with £0
Investing Articles
2 penny stocks with enormous potential
Investing Articles
This is the best-performing FTSE 100 stock of the last 40 years
Investing Articles
Here’s a 28p FTSE stock that has the potential to reach £1
Small-Cap Shares
3 high-growth penny stocks to consider buying for 2024
Investing Articles
1 hot UK growth stock I’m buying right now
Investing Articles
“My best-performing UK stock in 2023 has been…”
Investing Articles
This ex-penny stock just paid its first ever dividend. Here’s how much
1❯